This is therefore a contrasting of the dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation in NantKwest Inc. (NASDAQ:NK) and PDS Biotechnology Corporation (NASDAQ:PDSB). The two are both Biotechnology companies that compete with one another.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|PDS Biotechnology Corporation||7||0.00||N/A||-11.32||0.00|
Demonstrates NantKwest Inc. and PDS Biotechnology Corporation earnings per share, top-line revenue and valuation.
Table 2 provides the return on equity, return on assets and net margins of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|PDS Biotechnology Corporation||0.00%||-44.6%||-34.7%|
Risk and Volatility
NantKwest Inc. has a 2.34 beta, while its volatility is 134.00% which is more volatile than Standard and Poor’s 500. From a competition point of view, PDS Biotechnology Corporation has a 2.42 beta which is 142.00% more volatile compared to Standard and Poor’s 500.
The Current Ratio of NantKwest Inc. is 4.1 while its Quick Ratio stands at 4.1. The Current Ratio of rival PDS Biotechnology Corporation is 5 and its Quick Ratio is has 5. PDS Biotechnology Corporation is better equipped to clear short and long-term obligations than NantKwest Inc.
Insider and Institutional Ownership
The shares of both NantKwest Inc. and PDS Biotechnology Corporation are owned by institutional investors at 8.5% and 28.3% respectively. Insiders held roughly 21.5% of NantKwest Inc.’s shares. Insiders Competitively, held 6.5% of PDS Biotechnology Corporation shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|PDS Biotechnology Corporation||7.97%||7.62%||17.22%||-20.92%||-65.29%||1.25%|
For the past year NantKwest Inc. has stronger performance than PDS Biotechnology Corporation
PDS Biotechnology Corporation beats on 4 of the 7 factors NantKwest Inc.
NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer product candidates for the treatment of virally-induced cancers, such as polyoma virus induced merkel cell carcinoma, human papilloma virus induced cervical, and head and neck cancers; infectious diseases, including Ebola; and other serious viral, fungal, and bacterial infections. It is also develops high-affinity natural killer product candidates primarily for the treatment of solid tumors, breast cancer, head and neck/squamous, lymphoma, and various cancer; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the companyÂ’s proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.